Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virios Therapeutics, Inc. - Common Stock (NQ:VIRI)

0.1550 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virios Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Virios Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Announces New Social Media Profiles
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Virios Therapeutics CEO Highlights Novel Therapeutic Approach for Treating Fibromyalgia and Irritable Bowel Syndrome in Stock News Now Video Interview
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be... 
From Stock News Now
Via AccessWire
Topics Cannabis
News headline image
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Virios Therapeutics to Present at the SNN Network Summer Virtual Conference
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Featured in Bloomberg TV Interview
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics to Present at the Benzinga Global Small Cap Conference
From Virios Therapeutics, Inc.
Via Business Wire
News headline image
Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
News headline image
Virios Therapeutics to Present at the Needham Virtual Healthcare Conference
From Virios Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.